FY2025 EPS Estimates for ADMA Biologics Increased by Analyst

ADMA Biologics, Inc. (NASDAQ:ADMA) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for ADMA Biologics in a report issued on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn $0.73 per share for the year, up from their prior estimate of $0.70. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics Trading Down 4.7 %

NASDAQ:ADMA opened at $19.65 on Friday. ADMA Biologics has a one year low of $5.90 and a one year high of $23.64. The business has a fifty day moving average price of $16.74 and a 200-day moving average price of $18.01. The firm has a market capitalization of $4.65 billion, a price-to-earnings ratio of 70.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMA. Vanguard Group Inc. grew its stake in shares of ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock valued at $312,109,000 after acquiring an additional 80,302 shares during the period. State Street Corp boosted its position in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company’s stock worth $93,187,000 after purchasing an additional 50,399 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock valued at $80,065,000 after purchasing an additional 643,661 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of ADMA Biologics by 2.8% during the 4th quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company’s stock valued at $64,654,000 after buying an additional 102,692 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.